Review of the Clinical, Humanistic, and Economic Burden of Focal Segmental Glomerulosclerosis
The American Journal of Managed Care – 2026
Search Results
Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Resource type
Resource type
×Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Sort by
Publications
Results57
Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis
The American Journal of Managed Care – 2026
Sparsentan vs Irbesartan in Pediatric Patients With Focal Segmental Glomerulosclerosis
Kidney International Reports – 2026
Targeting Endothelin and Angiotensin Pathways for Kidney Function Preservation in Glomerular Disease
European Medical Journal – 2026
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Clinical Journal of the American Society of Nephrology – 2025
Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy
Glomerular Diseases – 2025
Congress materials
Results142
Antiproteinuric Effect of Sparsentanin Focal Segmental Glomerulosclerosis (FSGS) in the Ongoing 156-Week DUPLEX Open-Label Extension (OLE)
63rd European Renal Association (ERA) Congress – 2026
Use of Implementation Science to Optimize Management of Rare Kidney Disease
National Kidney Foundation (NKF) Spring Clinical Meetings – 2026
Proteinuria Reductions With Sparsentan (SPAR) Combined With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Adults With IgA Nephropathy (IgAN): A Single Site Case Series
National Kidney Foundation (NKF) Spring Clinical Meetings – 2026
In DUPLEX, Patients (Pts) With Focal Segmental Glomerulosclerosis (FSGS) Reached Low Proteinuria More Often With Sparsentan (SPAR) vs Irbesartan (IRB) Regardless of Baseline Proteinuria
National Kidney Foundation (NKF) Spring Clinical Meetings – 2026
In DUPLEX, Patients (Pts) With Focal Segmental Glomerulosclerosis (FSGS) Reached Low Proteinuria More Often With Sparsentan (SPAR) vs Irbesartan (IRB) Regardless of Baseline Proteinuria
National Kidney Foundation (NKF) Spring Clinical Meetings – 2026
Antiproteinuric Effect of Sparsentan (SPAR) After Maximized Irbesartan (IRB) in Patients (Pts) With Focal Segmental Glomerulosclerosis (FSGS) in the DUPLEX Open-Label Extension (OLE)
National Kidney Foundation (NKF) Spring Clinical Meetings – 2026
Events
Results21
Past
June 3–6, 2026 – Glasgow, Scotland
63rd European Renal Association (ERA) Congress 2026
Upcoming
June 23, 2026 – Chicago, IL
Path 2 Progress: Chicago
Past
May 6–10, 2026 – New Orleans, LA
National Kidney Foundation (NKF) Spring Clinical Meetings 2026
Past
April 24–27, 2026 – Boston, MA
97th Pediatric Academic Societies (PAS) Meeting 2026
Past
April 25–28, 2026 – New Orleans, LA
American Nephrology Nurses Association (ANNA) National Symposium 2026
Past
April 17, 2026 – Atlanta, GA
Path 2 Progress: Atlanta
Downloadable resources
Results7
KDIGO 2025 Infographic
FILSPARI US PI
FSGS Mechanism of Action
Travere Infographic-Overview of data on concomitant use of sparsentan and SGLT2i in IgA nephropathy
Travere Therapeutics – PROTECT 2-year findings Infographic Dec 2024
Kohan Infographic
Abstracts
Results48
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety Visual Abstract
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Sparsentan (SPAR) vs Irbesartan (IRB) in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial